Novartis hands off 3 preclinical programs to the antiviral R&D masters(02)

Dr. Cale Wiza IV
Novartis hands off 3 preclinical programs to the antiviral R&D masters


Image gallery: Top Daniel Oday Articles & Insights

Gilead locks in Daniel O’Day as CEO, tapping the Roche vet to Team building. Pipeline revamp. Forward thrust. What does a decade of Novartis hands off 3 preclinical programs to the antiviral R&D masters